MEMO PLUS GOLD is a natural memory enhancer, formulated from the extract of Bacopa monniera (well known as Brahmi) standardized as per the process know-how, developed and patented by Central Drug Research Institute (CDRI), India. MEMO PLUS GOLD is an Ayurvedic Drug, introduced after five decades of extensive research work by CDRI, on Bacopa monniera (commonly known as Brahmi), utilizing modern techniques. Bacopa monniera, a member of the Scrophulariaceae plant family, is one of the most revered in the ancient medical system called “Ayurveda” and has been used traditionally since 3000 years by everyone from school children to scholars.

The “enriched standardized extract of Bacopa monniera”, the active ingredient of MEMO PLUS GOLD, contains optimum levels of two active molecules Bacosides A & B, isolated and concentrated by CDRI. MEMO PLUS GOLD’s formulation is much more potent and has better mode of action than products based on extracts of Withania somnifera (Ashwagandha), Ginkgo biloba, Ginseng and Centella asiatica (Mandukaparni).

MEMO PLUS GOLD, facilitates learning, improves consolidation of learned behaviour and delay its extinction by enhancing the protein kinase activity and new protein synthesis, particularly in brain cells in areas connected with memory. MEMO PLUS GOLD, also induces an increase in protein, serotonin and lowers the epinephrine levels in the hippocampus, hypothalamus and cerebral cortex. The enhancements of protein, serotonin, and depletion of norephinephrine levels are indicative of the facilitatory effect of MEMO PLUS GOLD on long-term and intermediate forms of memory.

MEMO PLUS GOLD possesses a pronounced adaptogenic effect. In recent times, adaptation has emerged as a unique concept, as it helps the living beings to combat day-to-day stress and is therefore considered to be essential for survival. Further, research has proved that MEMO PLUS GOLD, has anti-anxiety & anti-depressant properties and is a powerful anti-oxidant.

MEMO PLUS GOLD is proven as safe & non-toxic by CDRI and credibly backed by successful clinical trials in India & Australia, which is appended below:

• CDRI clinical trials on ADHD (Attention Deficit Hyperactivity Disorder)Children.

• CDRI clinical trials on AAMI (AGE ASSOCIATED MEMORY IMPAIRMENT) - old age subjects.

• Swinburne University, AUSTRALIA, clinical trials on Healthy human volunteers - Published in Sychopharmacology-2001.

• University of Wollongong, clinical trials on Healthy human volunteers - Published in Neuropsychopharmacology-2002.

The results of the above clinical trials prove that Children show significant improvement in scores of several test systems, the Elderly subjects have considerable improvement in logical memory, digit forward, paired associated learning and in general improved higher order cognitive processes that are critically dependent on the input of information from our environment such as learning and memory for all age groups.